title: Portal vein thrombosis: should anticoagulation be used?
abstract: Portal vein thrombosis (PVT) can contribute to significant morbidity and mortality; in patients with cirrhosis, this can make transplant more technically challenging. Additionally, the clot may extend further into the mesenteric and splenic veins, and disturbance of the hepatic blood flow may lead to faster progression of the cirrhosis. Development of PVT is associated with local risk factors, and many patients have associated systemic prothrombotic factors. Anticoagulation in noncirrhotic patients should be initiated at diagnosis, using low-molecular-weight heparin overlapping with vitamin K antagonists. Cirrhotic patients with PVT should be screened for varices and then anticoagulated with low-molecular-weight heparin for at least a 6-month period. All patients should be assessed for triggering factors and tumors, as well as systemic prothrombotic factors. Newer evidence suggests that prophylactic anticoagulation in patients with cirrhosis may have a role in clinical management with decreased incidence of PVT and improved survival; further study is needed.
authors: Department of Medicine, University of Calgary Liver Unit, 3330 Hospital Drive NW, Calgary, AB, Canada, T2N 4N1.
authors: Stephen E
authors: SE
authors: Congly
authors: Samuel S
authors: SS
authors: Lee
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000075202:Contraindications; D004932:Esophageal and Gastric Varices / Q000175:diagnosis; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D011169:Portal Vein; D011170:Portasystemic Shunt, Surgical; D017410:Practice Guidelines as Topic; D020246:Venous Thrombosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy
chemical_list: D000925:Anticoagulants